Blockchain Registration Transaction Record

UHP Advances FDA Talks & CelluSTAT Gauze Shows Superior Safety in New Study

United Health Products updates FDA status on Warning Letter & releases new study data showing its CelluSTAT Hemostatic Gauze absorbs faster with less tissue reaction than standard care.

This news matters because it highlights progress for a medical device that could improve patient outcomes in common surgeries. If approved, CelluSTAT Hemostatic Gauze offers a potential alternative to current products, with new data suggesting it is absorbed faster and causes less tissue inflammation. This could reduce risks of post-surgical complications like chronic pain, infection, or issues with medical imaging, leading to better recovery for patients and potentially lowering healthcare costs. The company's engagement with the FDA is a critical step toward making this product available, impacting the future of surgical hemostasis and the medical device market.